Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07134127) titled 'A Study of IBI3032 in Chinese Healthy Subjects' on Aug. 14.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Other. Masking: Double (Participant, Investigator).
Primary Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center)
Condition:
Healthy
Intervention:
Drug: placebo
Recruitment Status: Not recruiting
Phase: Early Phase 1
Date of First Enrollment: August 25, 2025
Target Sample Size: 40
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07134127
Published by HT Digital C...